Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Hormonal Regulation of Blood Pressure

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spatially resolved label-free FTIR imaging reveals compartment-specific spectral signatures of cardiorenal crosstalk and their pharmacological modulation by Sacubitril/Valsartan.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026

Same author

Label-Free Detection of Molecular Signatures in Heart Failure with Preserved Ejection Fraction Using Raman Micro-Spectroscopy.

International journal of molecular sciences·2026

Same author

Effects of proANP<sub>31-67</sub> in a preclinical model of uninephrectomy and cardiac ischemia/reperfusion injury: cardiac remodeling and tissue biochemical profiling.

American journal of physiology. Cell physiology·2026

Same author

From Palpitations to Prevention: Timely Recognition of Biventricular ACM Preventing Sudden Cardiac Death.

Case reports in cardiology·2026

Same author

Sacubitril/valsartan preserves kidney function in rats with cardiorenal syndrome after myocardial infarction.

PloS one·2025

Same author

Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan-Meier-based individual patient data.

BMC medicine·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

B-type natriuretic peptide: beyond a diagnostic.

Fernando L Martin¹, Horng H Chen, Alessandro Cataliotti

¹Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA. martin.fernando@mayo.edu

Heart Failure Clinics

|September 2, 2008

Summary

B-type natriuretic peptide (BNP) is a key diagnostic marker for heart failure (HF). This review explores the therapeutic potential of BNP and its crucial role in HF management.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 2, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Published on: May 19, 2022

Area of Science:

Cardiology
Endocrinology
Pharmacology

Background:

The heart's function as an endocrine organ is recognized, notably with atrial natriuretic peptide.
B-type natriuretic peptide (BNP) is the second cardiac-secreted natriuretic peptide.
BNP is established as a vital diagnostic biomarker for heart failure (HF).

Purpose of the Study:

To review the therapeutic applications of B-type natriuretic peptide (BNP) in heart failure.
To examine the ongoing debate surrounding BNP's role as a therapeutic agent.
To highlight the significance of 3'5' cyclic guanosine monophosphate (cGMP) as a second messenger.

Main Methods:

Literature review of studies on BNP and its therapeutic implications in heart failure.
Analysis of the role of cGMP, the second messenger for BNP, nitric oxide, and phosphodiesterases.
Discussion of the modulation of cGMP by renal phosphodiesterases.

Main Results:

BNP is extensively utilized for diagnosing heart failure.
Controversy persists regarding the efficacy of BNP as a direct therapeutic intervention for HF.
The second messenger cGMP, influenced by renal phosphodiesterases, is critical for BNP's actions.

Conclusions:

BNP remains a cornerstone in heart failure diagnosis.
Further research is needed to clarify the therapeutic benefits of BNP in heart failure.
Understanding the cGMP pathway is essential for optimizing natriuretic peptide-based therapies.